| Detailed information |
|---|
| CancerLivER ID | 2470 |
| Biomarker | HSP27, Enoyl-CoA hydratase, Tubulin β chain, Galactose kinase, Ubiquinol-cytochrome C reductase complex core protein I, Annexin V, P-PST, Ribosome binding protein, Fumarylacetoacetase, ALDH, Catalase, |
| Biomarker Name/Symbol (given in Publication) | 11-proteins signature (Heat shock 27 kDa protein (HSP27), Enoyl-CoA hydratase, Tubulin β chain, Galactose kinase (Galactokinase), Ubiquinol-cytochrome C reductase complex core protein I, Annexin V, Phenol-sulfating phenol sulfotransferase 1 (P-PST), Ribosome binding protein, Fumarylacetoacetase, Aldehyde dehydrogenase (ALDH), Catalase ) |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | Both HBV- and HCV-associated HCC marker;but not validated on independent dataset |
| Experimental Condition | Both HBV- and HCV associated HCC tumor v/s non-tumorous |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Differentially expressed (P-PST, Ribosome binding protein, Fumarylacetoacetase, Catalase and ALDH are Downregulated and rest 6 are Upregulated) in HCC tumor v/s non-tumorous |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 14654528 |
| Type of Biomarker | Diagnostic |
| Pathway | NA |
| Cohort | Paired tumorous and surrounding nontumorous tissues obtained from 21 HCC patients. They were divided into three HCC types by viral markers: 7 hepatitis B surface antigen-positive (B-type HCC), 7 anti-HCV-positive (C-type HCC), and 7 hepatitis B surface antigen-negative and anti-HCV-negative. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Both HBV- and HCV-associated HCC |
| Year of Publication | 2003 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |